Find Reports
Select Report Type
Reimbursement Review
Displaying 676 - 700 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Arzerra | Ofatumumab | Chronic Lymphocytic Leukemia | Do not reimburse | Complete | PC0038-000 | |||
| Opsumit | Macitentan | Pulmonary arterial hypertension | List with clinical criteria and/or conditions | Complete | SR0364-000 | |||
| Gazyva | Obinutuzumab | Chronic Lymphocytic Leukemia | Reimburse | Complete | PC0041-000 | |||
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | SR0368-000 | |||
| Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | SR0367-000 | |||
| Invokana | Canagliflozin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | SR0370-000 | |||
| Anoro Ellipta | Umeclidinium/vilanterol | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | SR0371-000 | |||
| Yervoy | Ipilimumab | First Line Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | PC0042-000 | |||
| Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | SR0379-000 | |||
| Inflectra | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | List with criteria/condition | Complete | SE0384-000 | |||
| Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | SR0366-000 | |||
| Ultibro Breezhaler | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | SR0369-000 | |||
| Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | SR0375-000 | |||
| Botox | OnabotulinumtoxinA | Urinary incontinence | List with criteria/condition | Complete | SR0362-000 | |||
| Myrbetriq | Mirabegron | Overactive bladder | List with criteria/condition | Complete | SR0363-000 | |||
| Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | SR0354-000 | |||
| Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | SR0359-000 | |||
| Eylea | Aflibercept | Macular degeneration, age-related | List with criteria/condition | Complete | SR0361-000 | |||
| Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | SR0360-000 | |||
| Intuniv XR | Guanfacine hydrochloride | Attention-deficit/hyperactivity disorder (ADHD) | Do not list | Complete | SR0349-000 | |||
| Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | SR0352-000 | |||
| Abraxane | Nab-paclitaxel | Metastatic Pancreatic Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0037-000 | |||
| Zaltrap | Aflibercept | Metastatic Colorectal Cancer | Do not reimburse | Complete | PC0035-000 | |||
| Tivicay | Dolutegravir | HIV infection | List | Complete | SR0357-000 | |||
| Breo Ellipta | Fluticasone furoate /vilanterol | Chronic Obstructive Pulmonary Disease (COPD) | List with criteria/condition | Complete | SR0358-000 |
Health Technology Review
Displaying 576 - 589 of 589
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 676 - 700 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| pembrolizumab and lenvatinib | Reimbursement Review | Complete | PC0288-000 | ||||
| pembrolizumab | Reimbursement Review | Complete | PC0279-000 | ||||
| atezolizumab | Reimbursement Review | Complete | PC0269-000 | ||||
| semaglutide | Reimbursement Review | Complete | SR0725-000 | ||||
| atezolizumab | Reimbursement Review | Complete | PC0277-000 | ||||
| tepotinib | Reimbursement Review | Complete | PC0255-000 | ||||
| Bevacizumab for the Treatment of Patients with Brain Radionecrosis | Health Technology Review | Rapid Review | Completed | RC1465-000 | |||
| Subtypes of Post-COVID-19 Condition | Health Technology Review | Technology Review | Completed | HC0035-000 | |||
| NSCLC without actionable oncogenic alterations | Reimbursement Review | Provisional Funding Algorithm | Completed | PH0015-000 | |||
| Oseltamivir for the Prevention of Influenza in Residents of Long-Term Care Facilities | Health Technology Review | Rapid Review | Completed | RC1464-000 | |||
| asciminib | Reimbursement Review | Complete | PC0275-000 | ||||
| dostarlimab | Reimbursement Review | Complete | PC0263-000 | ||||
| Octreotide Long-Acting Release and Everolimus for Recurrent Meningiomas | Health Technology Review | Rapid Review | Completed | RC1462-000 | |||
| Body Mass Index as a Measure of Obesity and Cut-off for Surgical Eligibility | Health Technology Review | Technology Review | Completed | HC0048-000 | |||
| faricimab | Reimbursement Review | Complete | SR0719-000 | ||||
| Multiple Myeloma (MM) | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0014-000 | |||
| Treatment Options for VEXAS Syndrome | Health Technology Review | Rapid Review | Completed | RC1460-000 | |||
| CADTH Pharmaceutical Reviews Update — Issue 32 | Reimbursement Review | Pharmaceutical Review Update | |||||
| Intravenous Iron Preparations for Patients Undergoing Elective Surgery: A 2022 Update | Health Technology Review | Rapid Review | Completed | RC1457-000 | |||
| Peer Support Programs for Youth Mental Health | Health Technology Review | Health Technology Assessment | Completed | HT0036-000 | |||
| nusinersen | Reimbursement Review | Complete | SR0713-000 | ||||
| Raltitrexed in patients with dihydropyrimidine dehydrogenase (DPD) deficiency | Health Technology Review | Reference List | Completed | RC1463-000 | |||
| Transanal Total Mesorectal Excision for Adult Patients with Rectal Cancer | Health Technology Review | Rapid Review | Completed | RC1459-000 | |||
| mogamulizumab | Reimbursement Review | Complete | PC0244-000 | ||||
| abaloparatide | Reimbursement Review | Withdrawn | SR0744-000 |